{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:14:19Z","timestamp":1791951259239,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01 AI117287"],"award-info":[{"award-number":["R01 AI117287"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U19 AI109946"],"award-info":[{"award-number":["U19 AI109946"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centers of Influenza Virus Research and Surveillance (CEIRS)","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cmi.2017.02.009","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T10:12:55Z","timestamp":1486980775000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["Universal influenza virus vaccines and therapeutic antibodies"],"prefix":"10.1016","volume":"23","author":[{"given":"R.","family":"Nachbagauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.02.009_bib1","series-title":"WHO Fact sheet 211: Influenza","author":"Organization WH","year":"2009"},{"key":"10.1016\/j.cmi.2017.02.009_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/1471-2458-14-813","article-title":"Annual public health and economic benefits of seasonal influenza vaccination: a European estimate","volume":"14","author":"Preaud","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cmi.2017.02.009_bib3","first-page":"1057","article-title":"Estimates of deaths associated with seasonal influenza \u2013 United States, 1976-2007","volume":"59","author":"(CDC) CfDCaP","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2017.02.009_bib4","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.1038\/srep09540","article-title":"Estimating influenza attack rates in the United States using a participatory cohort","volume":"5","author":"Chunara","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2017.02.009_bib5","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1038\/nm1141","article-title":"Influenza: old and new threats","volume":"10","author":"Palese","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2017.02.009_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/biot.201400393","article-title":"Emerging influenza viruses and the prospect of a universal influenza virus vaccine","volume":"10","author":"Krammer","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.cmi.2017.02.009_bib7","doi-asserted-by":"crossref","first-page":"20248","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.02.009_bib8","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2017.02.009_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C","article-title":"Mismatch between the 1997\/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly","volume":"61","author":"de Jong","year":"2000","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib10","doi-asserted-by":"crossref","unstructured":"Xie H, Wan XF, Ye Z, Plant EP, Zhao Y, Xu Y, et\u00a0al. H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. Sci Rep 5:15279","DOI":"10.1038\/srep15279"},{"key":"10.1016\/j.cmi.2017.02.009_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2017.02.009_bib12","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A\u00a0common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J\u00a0Virol"},{"issue":"12","key":"10.1016\/j.cmi.2017.02.009_bib13","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmi.2017.02.009_bib14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2017.02.009_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.cmi.2017.02.009_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The Quest for a Universal Flu Vaccine: Headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2017.02.009_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib18","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.02481-15","article-title":"Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets","volume":"90","author":"Nachbagauer","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"Dilillo","year":"2014","journal-title":"Nat Med"},{"issue":"6254","key":"10.1016\/j.cmi.2017.02.009_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A\u00a0stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.02.009_bib21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2017.02.009_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"npj Vaccines"},{"key":"10.1016\/j.cmi.2017.02.009_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2017.02.009_bib24","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2017.02.009_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s15010-013-0546-4","article-title":"Development of universal influenza vaccines based on influenza virus M and NP genes","volume":"42","author":"Zheng","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2017.02.009_bib26","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2017.02.009_bib27","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J\u00a0Hyg (Lond)"},{"key":"10.1016\/j.cmi.2017.02.009_bib28","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1016\/j.vaccine.2014.07.012","article-title":"Seasonal influenza vaccine dose distribution in 157 countries (2004-2011)","volume":"32","author":"Palache","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2017.02.009_bib29","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1128\/JVI.00469-12","article-title":"A\u00a0pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in\u00a0vivo","volume":"86","author":"Tan","year":"2012","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib30","doi-asserted-by":"crossref","first-page":"8272","DOI":"10.1128\/JVI.00969-13","article-title":"In\u00a0vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies","volume":"87","author":"Heaton","year":"2013","journal-title":"J\u00a0Virol"},{"issue":"6044","key":"10.1016\/j.cmi.2017.02.009_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A\u00a0highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.02.009_bib32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1073\/pnas.1319058110","article-title":"A\u00a0common solution to group 2 influenza virus neutralization","volume":"111","author":"Friesen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.02.009_bib33","doi-asserted-by":"crossref","first-page":"13580","DOI":"10.1128\/JVI.02289-14","article-title":"Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin","volume":"88","author":"Tan","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib34","doi-asserted-by":"crossref","first-page":"e1000796","DOI":"10.1371\/journal.ppat.1000796","article-title":"Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins","volume":"6","author":"Wang","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2017.02.009_bib35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1172\/JCI74374","article-title":"Preexisting human antibodies neutralize recently emerged H7N9 influenza strains","volume":"125","author":"Henry Dunand","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2017.02.009_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"6044","key":"10.1016\/j.cmi.2017.02.009_bib37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A\u00a0neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.02.009_bib38","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.02.009_bib39","doi-asserted-by":"crossref","first-page":"10446","DOI":"10.1128\/JVI.01284-16","article-title":"Human monoclonal antibody 81.39a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins","volume":"90","author":"Marjuki","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2017.02.009_bib40","first-page":"5437","article-title":"An in\u00a0vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies","volume":"60","author":"Nakamura","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.02.009_bib41","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/AAC.00607-16","article-title":"Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers","volume":"60","author":"Lim","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.02.009_bib42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.cmi.2017.02.009_bib43","doi-asserted-by":"crossref","first-page":"e1005702","DOI":"10.1371\/journal.ppat.1005702","article-title":"Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody","volume":"12","author":"Chai","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2017.02.009_bib44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2017.02.009_bib45","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1073\/pnas.1502374112","article-title":"A\u00a0broadly neutralizing human monoclonal antibody is effective against H7N9","volume":"112","author":"Tharakaraman","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.02.009_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMed"},{"key":"10.1016\/j.cmi.2017.02.009_bib47","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.02.009_bib48","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1038\/ncomms8708","article-title":"A\u00a0potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus","volume":"6","author":"Wu","year":"2015","journal-title":"Nat Commun"},{"issue":"6100","key":"10.1016\/j.cmi.2017.02.009_bib49","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.02.009_bib50","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.cmi.2017.02.009_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2-based influenza vaccines: recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2017.02.009_bib52","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.cmi.2017.02.009_bib53","doi-asserted-by":"crossref","first-page":"e14442","DOI":"10.1371\/journal.pone.0014442","article-title":"Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin","volume":"5","author":"Talbot","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cmi.2017.02.009_bib54","doi-asserted-by":"crossref","first-page":"e48322","DOI":"10.1371\/journal.pone.0048322","article-title":"A\u00a0T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.02.009_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.02.009_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062778","article-title":"Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine","volume":"8","author":"Powell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.02.009_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.cmi.2017.02.009_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.cmi.2017.02.009_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.02.009_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and immunogenicity of multimeric-001\u2013a novel universal influenza vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2017.02.009_bib61","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1016\/j.vaccine.2014.08.031","article-title":"Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population","volume":"32","author":"Atsmon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2017.02.009_bib62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.vaccine.2014.06.006","article-title":"A\u00a0novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety","volume":"33","author":"Francis","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2017.02.009_bib63","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/CVI.00098-15","article-title":"A\u00a0Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans","volume":"22","author":"Pleguezuelos","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2017.02.009_bib64","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17300976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17300976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T03:57:40Z","timestamp":1717300660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17300976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1198743X17300976"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.02.009","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universal influenza virus vaccines and therapeutic antibodies","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2017.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}